Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda to Launch New Manufacturing Facility for Leuplin; Aims to Maintain Its 110 Billion Yen Sales
May 29, 2019
- Insulin/GLP-1 Receptor Agonist Combo Demonstrates Efficacy in Japan PIII: Sanofi
May 29, 2019
- NEC Ties Up with French Biotech to Develop Neoantigen Vaccines Using AI
May 28, 2019
- Ribomic Files Patent for Aptamer Therapeutic, Ends Licensing Pact with Otsuka
May 27, 2019
- Hisamitsu’s Hyperhidrosis Drug Hit Main Goal in Japan PII
May 27, 2019
- Hisamitsu One Step Closer to FY2019 Filing after NSAID Patch Delivers Positive PIII in Cancer Pain
May 27, 2019
- AbbVie’s Psoriasis Drug Skyrizi Makes Debut in Japan
May 27, 2019
- MSD’s Zerbaxa Launch Being Shelved after Foreign Particles Detected
May 27, 2019
- Big 3 Generic Makers Eke Out Growth in Japan, but Struggle in US; AG Momentum Continues: Jiho Tally
May 24, 2019
- Daiichi Sankyo Denies Report on Sales Deal on Its OTC Subsidiary
May 24, 2019
- Shionogi in Marketing Tie-Up with Molteni for Rizmoic
May 23, 2019
- Ono Offers Its Account of License Fee Row with Nobel Laureate
May 23, 2019
- Trelegy Hits Japan Shelves, Novartis Starts Accepting Orders for Kymriah
May 23, 2019
- AbbVie’s Japan Sales in 2018 Double on Maviret Boon
May 23, 2019
- Chugai to Set Up Research Base in Yokohama, Shutter 2 Labs
May 22, 2019
- Japan Pharma Market Shrinks 1.8% in FY2018: IQVIA
May 22, 2019
- 1st Oral Proceedings Held for Bayer Employee Damage Suit
May 21, 2019
- Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
- Daiichi Sankyo Returns Part of Govt Grant for H5N1 Influenza Vaccine Project after Missing Supply Target
May 21, 2019
- Taisho Completes Tender Offer for Vietnamese Drug Maker
May 21, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…